It has been shown that intratumor administration of an adenovirus vector expressing IL-12 produces a potent T cellmediated response that leads to significant tumor regression in a murine breast cancer model. IP-10 and MIG are CXC chemokines that recruit mononuclear cells in vivo. In addition to their chemotactic roles, IP-10 and MIG inhibit angiogenesis. We tested whether the addition of IP-10 or MIG may both enhance the antitumor immune response of IL-12 through T cell recruitment and inhibit tumor growth through angiostasis. Adenovirus vectors expressing IP-10 or MIG and/or IL-12 were administered intratumorally in a
Introduction
Cancer, a leading cause of death in the industrialized world, results from the progressive growth of progeny from a single transformed cell. Surgical excision, chemotherapy and radiation treatments are presently used to destroy malignant cells. Destruction of all the malignant cells is essential in the treatment of cancer if the therapy is to provide long-standing tumor-free protection. As an alternative approach, promising new therapies involving stimulation of an antitumor immune response are being developed employing different strategies to enhance the immunogenicity of tumors. These include the introduction of genes that encode co-stimulatory molecules, such as B7, or cytokines, such as interleukin-12 (IL-12), into tumor cells. [1] [2] [3] [4] [5] Many cytokines, including interleukin-12 (IL-12), possess significant antitumor activity in mice. 2, 6 IL-12, a heterodimeric protein comprised of two disulfide-linked subunits (p40 and p35), is secreted by macrophages and dendritic cells and is a critical mediator of immune responses. 7 The biological activities of IL-12 include the ability to enhance Th1-mediated immune responses, natural killer (NK) and cytotoxic T lymphocyte (CTL) activities. It also induces the expression of cytokines, such as interferon (IFN␥) from NK and T cells. As a result, IL-12 administration is being pursued as a therapy for neoplasia. established, poorly immunogenic tumors in various murine models. 2, 6 Although the antitumor effects of IL-12 have been attributed to its ability to stimulate immunity, antitumor activity has also been observed, to a lesser extent, in immune-comprised animals, suggesting that non-immune mechanisms may also be involved. 6, 8 The up-regulation of IFN␥ by IL-12 leads to the synthesis of a number of different proteins, including the chemokine interferon inducible protein 10 (IP10) and monokine induced by gamma (MIG). 9, 10 IP10 and MIG are structurally related CXC chemokines markedly induced by IFN␥, but unlike other CXC chemokines, IP-10 and MIG lack the ELR sequence motif and are not chemotactic for neutrophils. [9] [10] [11] IP-10 and MIG share the same receptor (CXCR3) and are chemotactic for activated T lymphocytes and natural killer cells. 10, [12] [13] [14] [15] In addition to their pronounced chemotactic activities both have been shown to inhibit angiogenesis. [16] [17] [18] IP10 and MIG exhibit antitumorigenic properties, an effect thought to be the result of their action on lymphocytes as well as their anti-angiogenic properties. [17] [18] [19] [20] In the RENCA tumor model in mice, induced endogenous IP10 and MIG appear necessary for IL-12-mediated regression. 21 We have previously shown that intratumoral administration of an adenoviral vector expressing murine IL-12 causes significant regression of a transgenic breast cancer tumor model associated with overexpression of the polyoma middle T antigen (PyMT). 2 However, we and others observed significant toxicity with high doses of IL-12 and this toxicity appears mainly to be due to IFN␥ up-regulation by IL-12. 22 Therefore, the addition of mediators downstream of IL-12 and IFN␥ may enhance the therapeutic effects of a lower dose of IL-12 without increasing toxicity. Either IP-10 or MIG may enhance the antitumor immune response of IL-12 both through activated T cell recruitment and inhibition of tumor growth through their anti-angiogenic properties. To examine this, replicationdeficient adenovirus vectors expressing human IP-10 (AdIP-10) or MIG (AdMIG) and/or murine IL-12 (AdIL-12) were administered intra-tumorally in murine models of mammary adenocarcinoma and MCA207 sarcoma.
Results
Expression of MIG and IP-10 in virally infected MCA207 cells To examine expression of MIG or IP-10 in adenoviral vector infected MCA 207 tumor cells total RNA was isolated 24 h after infection and examined by Northern blot. AdIP-10 infected cells expressed abundant IP-10 mRNA while AdMIG infected cells expressed abundant MIG mRNA ( Figure 1) . These results in a relevant tumor line and our previously published data showing intranasal/ intratracheal administration of Ad (CXC chemokine) produced prolonged expression of biologically active IP-10 or MIG in the lung 23 indicate that the Ad (CXC chemokine) vectors can express biologically active chemokine within tumor tissue when administered by direct intratumor injection.
In vivo inhibition of angiogenesis (Matrigel)
In Balb/c nude mice a reduction in endothelial cell infiltration was observed in the Matrigel plugs of animals treated with AdIP-10, AdMIG or AdIL-12 as compared with control virus-treated animals. Percentage area occupied by endothelial cells was reduced from 27.7 ± 5.2% in plugs containing bFGF + control virus to 5.2 ± 1% in AdIP-10 or 11 ± 2.6% in AdIL-12-treated Matrigel plugs. Therefore, AdIP-10 and AdIL-12 treatment in vivo result in a significant (P Ͻ 0.05) reduction in angiogenesis.
Tumor regression induced by adenoviral constructs AdIP-10, AdMIG and AdIL-12 either alone or in combination were tested for the their ability to regress tumors (Figures 2, 3 ; Table 1 ).
Previously, it has been suggested that the antitumor activity of IL-12 maybe due to up-regulation of IP-10 and MIG. 21 We examined this by combining AdIP-10 and AdMIG in the PyMT tumor model. A combination of AdIP-10 and/or AdMIG resulted in no complete regressions, but was more effective at inducing a partial response than either chemokine alone (100% for the combination, 60% with AdMIG and 42% with IP-10). This suggests that IL-12 antitumor action (14% PyMT and 40% MCA207 complete regression) is not due solely to the up-regulation of these chemokines (Figure 2b ).
CTL activity in cured AdIP-10 + AdIL-12-treated-PyMT mice To determine whether the adenovirus vector treatment induced a tumor-specific CTL response, cured mice (AdIP-10 +AdIL-12 treated) were killed and their spleens removed 90 days following PyMT rechallenge. Splenocytes prepared from tumor regressed AdIP-10 + AdIL-12-treated mice demonstrated a 30% specific lysis of 516MT3 cells at an effector to target ratio of 90:1 ( Figure 4 ). Minimal background lysis was observed. These results suggest cytotoxic T lymphocyte activity directed against the PyMT antigen is present in cured AdIP-10 + AdIL-12-treated mice.
Regression of untreated distal PyMT tumors following administration of AdIP-10 in combination with AdIL-12.1 The presence of tumor-specific CTLs in the spleens of cured animals treated with AdIP-10 in combination with AdIL-12 suggests that there should be circulating tumorspecific T cells that may recognize distal tumors. To test this hypothesis, animals bearing bilateral tumors were injected with either control virus or AdIP-10 in combination with AdIL-12 in the right flank tumor only and tumor growth on both flanks was monitored. Of the animals that showed complete regression on the injected flank (seven of 14, 50%), 60% also showed complete regression on the opposite flank. Control virus had no effect on either treated or untreated distal tumors. These results indicate that direct intratumor treatment with AdIP-10 in combination with AdIL-12 was effective at inducing potent systemic immunity.
Generation of long-term systemic immunity to PyMT tumor cell re-challenge Mice that had undergone complete regression of the PyMT tumor when treated with AdIP-10 + AdIL-12 were re-challenged with a second inoculation of 10 6 PyMT cells 8 weeks after initial vector administration, on the left hind flank. None of the challenged mice developed tumors and all (nine of nine) remained tumor free for 8 weeks after challenge. One hundred percent of control (naive) untreated syngeneic animals developed palpable tumors within 21 days after injection. These results suggest AdIP-10 + AdIL-12 induced tumor regression and induced long-term antitumor immunity.
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Quantification of murine IL-4 and IFN␥ in PyMT tumors
Intratumoral administration of AdIP-10 + AdIL-12 led to dramatic increases in IFN␥ concentration in tumor homogenates as compared with AdIP-10, AdIL-12 or control virus-treated tumors (2480 ± 372 pg/ml for AdIP-10 + AdIL-12-treated tumors compared with 392 ± 224 pg/ml for AdIP-10, 488 ± 102pg/ml for AdIL-12 and 56 ± 12 pg/ml for control-treated tumors). In contrast, IL-4 was undetectable in control or AdIP-10 + AdIL-12-treated tumor homogenates.
PyMT tumor immunohistochemistry
To characterize further the antitumor activity of these vectors in vivo, we determined the phenotype of lymphocytes that had accumulated in the PyMT tumors 3 days after adenoviral administration. In control vector-treated tumors limited lymphocyte infiltration was observed (8.0 ± 1.2 CD3
+ cells per high power field (HPF)) 3 days after + T cells were predominant, however, considerable numbers of CD4 + cells were also present (Table 2) .
In tumors treated with AdIP-10, decreased CD31-positive staining was observed when compared with control- treated animals, demonstrating a direct angiostatic activity within the tumor ( Figure 5 ).
Discussion
Activation of the immune system is vital in the rejection of neoplastic cells. However, many potentially antigenic tumors have developed mechanisms to evade and suppress the immune system. Overcoming the mechanisms of tumor-mediated immune suppression and stimulation of an antitumor immune response are major goals of cancer immunotherapy. Previously, it has been shown that certain cytokines, such as IL-12 and IL-2, can stimulate an anticancer immune response and mediate tumor regression. 2, 4, 6, 25 However, many of these therapies when administered systemically are limited by toxic sideeffects. 22 Such toxicities can be reduced by local administration of the cytokine. We and others have used replication-deficient adenoviral vectors to deliver cytokine genes directly into the tumor and have shown that transient local expression of cytokines such as IL-12 can lead to significant tumor regression.
1,2 However, even with restricted tissue expression of the gene and local proa b
Figure 5 Inhibition of angiogenesis in the PyMT tumor following direct injection with AdIP-10. Following palpable tumor formation, AdIP-10 or control adenovirus was intratumorally injected. PyMT tumors were removed 7 days after administration of vectors. All tumors were frozen in OCT compound and stored at −70°C. Frozen sections (3-5 m) were subjected to anti-CD31 immunohistochemistry. In AdIP-10-treated tumors (a) reduced CD31 staining for endothelium (arrows) is observed when compared with control virus-treated animals (b) (original magnification × 200).
duction of IL-12, at high doses systemic toxicities can still be exhibited.
We have used a number of different approaches to amplify the antitumor activity of IL-12 while reducing the toxicity observed. The addition of co-stimulatory molecules, such as B7.1 enhances IL-12-mediated tumor regression. 3 We have also shown that administration of an adenovirus vector expressing IL-12 in combination with a lymphocyte-specific chemokine, lymphotactin, dramatically increases tumor regression and survival time. 26 In this study, we have examined the effect of coadministration of the CXC chemokines IP-10 or MIG with AdIL-12 on tumor regression to determine whether combinations of chemotaxis and anti-angiogenesis might be effective. Similar to lymphotactin, IP-10 and MIG are chemotactic for T lymphocytes as well as other mononuclear cells. 10, 13, 14, [27] [28] [29] In an earlier study, we showed that local administration of AdIP-10 results in marked accumulation of CD4 + and CD8 + T cells as well as NK cells and secondary accumulation of monocytes and neutrophils through factors released by the activated T cells. AdMIG produced biologically active chemokine in vivo and the chemotactic activity of MIG was very similar to IP-10 (in both cell type and magnitude). 23 In the absence of a suitable immunoassay for IP-10 or MIG, we take these data to indicate that the vectors release similar levels of chemokine. We show here that these same vectors are also effective at inhibiting angiogenesis in a bFGFmediated Matrigel angiogenesis assay, as was AdIL-12 in this assay. Thus, administration of AdIL-12 in combination with either AdIP-10 or AdMIG should result in marked inhibition of tumor growth, accumulation of appropriate T cell populations and enhanced immune responses directed towards specific tumor antigens.
Administration of AdIP-10 or AdMIG in combination with AdIL-12 resulted in substantial (synergistic) increases in tumor regression as compared with AdIP-10, AdMIG, AdIL-12 or control-treated animals. In both the PyMT breast cancer model and the MCA207 fibrosarcoma model, a combination of AdIL-12 and AdIP-10 was more effective (45% and 60% complete regression, respectively) than AdMIG (10% and 20% complete regression, respectively). Neither chemokine alone was able to induce total regression in any model but were both able to cause a considerable delay in tumor progression (Table 1, Figures 2, 3) . Other studies have shown that CD4 + T cells are crucial to the development of an antitumor immune response. 30 Intratumor administration of AdIP-10 leads to increased CD4 + T cell infiltrating the tumor. The IP-10 and MIG receptor, CXCR3, has been shown to be preferentially expressed on T H 1 CD4 + cells. 12, 31, 32 Therefore, the CD4 + T cells migrating into the tumor following treatment by AdIP-10 or AdMIG should be of the T H 1 phenotype. This is supported by the data showing profound IFN␥ levels in the tumor, with no detectable IL-4, after the IP-10/IL-12 combination was administered to the tumor (approximately eight-fold over any of the single vectors). The induction of IFN␥ by AdIL-12 confirms an earlier finding with intratumor injection. 2 This confirms the T H 1 nature of the response and suggests that the presence of CD4 + T cells induced by IP-10 may contribute to the beneficial CD8 + CTL response seen. The critical role of IFN␥ for IL-12-mediated antitumor activity has been examined. IFN␥ depletion has been previously shown to inhibit IL-12-mediated infilGene Therapy tration of lymphoid cells to the tumor site. 33 In addition to immune effects, IL-12 has been shown to inhibit tumor angiogenesis. 34 Inhibition of angiogenesis can also be inhibited by IFN␥ depletion. 35 As a result of these previously published findings, we expect administration of AdIL-12 in IFN␥-deficient mice would have little antitumor activity. However, this would require extensive backcross developments, as there are no IFN␥ knockout mice available on the FVB genetic background.
Consistent with the finding of circulating CTL in regressed mice, all mice that exhibited complete regression were protected against subsequent tumor cell challenge. In addition, AdIP-10 + AdIL-12 treatment was effective in mediating the regression of distal (contralateral side) untreated tumors. These results suggest that treatment with CXC chemokines in combination with IL-12 generates long-term systemic immunity.
Enhancement of the antitumor immune response is not the only mechanism by which CXC chemokines in combination with IL-12 may inhibit tumor growth. Nonimmune mechanisms, such as the inhibition of tumor angiogenesis may be involved. Previously, IL-12, MIG and IP-10 have been shown to inhibit tumor angiogenesis. [16] [17] [18] [19] [36] [37] [38] Both chemokines block angiogenesis as seen in the Matrigel assay. Direct examination for vascular structure in the tumor demonstrated decreased vasculature in tumors treated with AdIP-10 as compared with control-treated tumors ( Figure 5 ). This inhibition of angiogenesis probably leads to the marked growth delay and partial regression observed with the chemokine vectors.
We also examined the ability of IP-10 and MIG to directly mimic the antitumor effects of IL-12. Previously, others have demonstrated that the antitumor activities of IL-12 (both the T cell-mediated and anti-angiogenic activity) are dependent on the presence of IP-10 and MIG. 21, 38 Neutralizing antibodies to IP-10 and MIG partially abrogates IL-12-mediated regression in the RENCA model. 21 Combinations of AdIP-10 and AdMIG lead to significant impairment of tumor progression (100% of animals showed partial regression or delayed growth) indicating increased effects on vascular development. However, the combination did not induce any complete regression and all animals treated (nine of nine) succumbed to tumor growth (Figure 2 ). These data suggest that the antitumor activities of IL-12 are not completely mediated by the CXC chemokines IP-10 and MIG and that these chemokines alone cannot induce protective immunity. These results using combinations of CXC chemokines IP-10 and MIG which lead to accumulation of T cells as well as other inflammatory cells compare favorably with the data previously obtained using a single vector expressing IL-12 and lymphotactin. 26 In each case, there were increases in local accumulation of T cells and enhanced IL-12-induced CTL responses. Lymphotactin vectors alone were able to induce limited complete regression in the PyMT tumor model (15% lymphotactin alone versus 75% for IL-12 + lymphotactin) whereas the CXC chemokines could not induce a similar effect by themselves. 26 This may point to different populations and activation effects on T cells by CXC and C chemokine families. The data also suggest that angiostatic effects alone could enhance the ability of AdIL-12 to induce protective immunity by limiting tumor growth and potentially introducing tumor antigen processing through necrosis or apoptosis of the tumor shown to increase tumor immunogenicity. 39, 40 Both MIG and IP-10 can lead to focal necrosis in tumors. 18, 19 (We observed significant necrosis in tumors following AdIP-10 treatment, data not shown.) Indeed, in a separate study, we have used a vector expressing angiostatin, a protein that is directly angiostatic and is not chemotactic for T cells, to cause enhanced protection by IL-12 administration in a similar tumor model (Gyorffy et al, manuscript submitted) . Whether IP-10 or MIG exhibit additional benefits over and above angiostasis needs to be addressed in other tumor models.
These data expand the repertoire of vectors known to affect tumor growth when directly administered to the tumor. Combinations of cytokine, co-stimulatory molecules, chemokines and/or angiostatic molecules all enhance the direct effect of immune stimulatory cytokines such as IL-12 or IL-2. Which combination(s) will be effective may depend on the type and distribution of tumor under treatment. In addition, combinations such as used here have a positive impact on the induction of immunity and should be useful as adjuvants for more general applications in vaccine development. Combinations of chemokines specific for T cells and dendritic cells may enhance the activity of immunostimulatory cytokines, while co-exisitng angiostatic activity may prevent tumor progression and lead to enhanced tumor destruction and antigen presentation. Vectors that will allow incorporation of multiple genes encoding these various activities should prove beneficial for tumor immunotherapy and vaccine efficacy.
Materials and methods
Recombinant adenoviruses
The vectors expressing human IP-10 (AdIP-10) and murine MIG (AdMIG) were constructed as previously described. 23 Each vector was shown to express mRNA, protein and biological activity. AdIL-12.1, an Ad vector expressing murine IL-12, was constructed as previously described. 2 The control vector Ad5 dl70-3 was constructed as previously described. 25 RNA isolation and Northern blot analysis MCA 207 cells in a 75-cm 2 tissue culture flask were infected with AdIP-10 or AdMIG (100 p.f.u. per cell). After 24 h the virally infected cells were collected. Total RNA was isolated by standard methods with TRIZOL (Gibco BRL, Burlington, ON, Canada). Northern blot analysis was performed by standard procedures using 
Quantification of murine IL-4 and IFN-␥ in PyMT tumors
Tumors were removed from treated animals 3 days after adenovirus administration. The tumors were then homogenized in 500 l PBS. The samples were centrifuged at 10 000 r.p.m. for 5 min. The supernatants were analyzed for murine interleukin 4 (IL-4) and interferon-␥ (IFN␥ using ELISA kits (R & D Systems, Minneapolis, MN, USA). The sensitivities of the IL-4 and INF␥ ELISAs were 2 pg/ml for their respective cytokines.
Determination of CD3
+ , CD4
+ and CD8 + T lymphocytes in treated PyMT tumors Immunohistochemistry was used to determine the lymphocyte subsets infiltrating PyMT tumors after treatment with all vectors. Tumors were removed 3 days after administration of various vectors. All tumors were frozen in OCT compound and stored at −70°C. Frozen sections (3-5 m) were processed from the frozen tumors and subjected to anti-CD3 (rabbit anti-human CD3; Dako, Carpinteria, CA, USA), anti-CD4 (anti-mouse CD4, L3T4; PharMingen, San Diego, CA, USA), and anti-CD8 (antimouse CD8a; Ly-2; PharMingen) immunohistochemistry. To determine the relative numbers of CD3 + , CD4
+ , and CD8 + T cells in tumors five high power fields (HPF) were randomly selected per section and positively staining cells were counted and averaged.
Determination of vasculature in treated PyMT tumors
Tumor vasculature following adenovirus administration (AdIP-10 or control virus) was examined using immunohistochemistry. PyMT tumors were removed 7 days after administration of vectors. All tumors were frozen in OCT compound and stored at −70°C. Frozen sections (3-5 m) were processed from the frozen tumors and subjected to anti-CD31 immunohistochemistry (rat antimouse CD31; PharMingen).
In vivo inhibition of angiogenesis (Matrigel) by AdIP-10 and AdMIG Matrigel (Collaborative Biomedical Products, Bedford, MA, USA), basement membrane extract, forms a gel when injected subcutaneously into mice. When supplemented with angiogenic factors, such as basic fibroblast growth factor (bFGF), vasculature develops within the Matrigel. Recombinant adenovirus (control adenovirus, AdIP-10, AdMIGor AdIL-12, 10 9 p.f.u.) was suspended in cold Matrigel (500 l) containing 150 ng/ml recombinant bFGF (Gibco BRL). The adenovirus Matrigel mixture was injected subcutaneously in Balb/c nude mice where it polymerized to form a plug. Seven days after injection, the Matrigel plug was removed, fixed in 10% buffered formalin, embedded in paraffin, sectioned and stained with Masson's Trichrome. Endothelial cell infiltration was determined using a Zeiss microscope (North York, ON, Canada) equipped with a Sony CCD digital camera (Toronto, ON, Canada). Five medium power fields (× 200) at the tissue matrigel interface were examined and endothelial cell inflitration was quantified using Northern exposure imaging software.
Data analysis
Data are expressed as mean ± s.e.m. Whenever suitable, results were interpreted using ANOVA test with the Fisher LSD method. Differences were considered significant when P Ͻ 0.05.
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